Overview

Cilengitide in Treating Patients With Prostate Cancer

Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well cilengitide works in treating patients with prostate cancer. Cilengitide may stop the growth of prostate cancer by blocking blood flow to the tumor
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)